Since my last article on PAVmed (PAVM) on September 26, PAVM's share price tripled to a little over $3 late February before falling back a little to about $2.60 today, presenting another buying opportunity based on FDA approval of CarpX on April 21, and other upcoming catalysts involving progress on their medical devices. This article will focus more on recent developments, but readers can gain a lot of background on the company's devices and management from my previous article as well as Shareholders Unite's article on December 8. Detailed device descriptions, market opportunities, and strategy